Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos

This article was originally published in The Pink Sheet Daily

Executive Summary

AMAG shareholders have killed plans for what they considered an ill-conceived merger and one shareholder calls the vote a "clear signal" that current management isn't fit to run the company.

You may also be interested in...



AMAG’s Feraheme Expansion Strategy Delayed For Now

FDA has extended by three months its review of a sNDA for the I.V. iron product that would expand the drug’s use into a far broader patient population.

Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans

The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.

People In The News: Changes At EnVivo, CSL, Biomed, Orexo, NCPA, And More

Deborah Dunsire takes top leadership post at EnVivo and Paul Perreault at CSL Limited; Robert DeLuca to lead U.S. rollout of Orexo’s Zubsolv; Former CMS Deputy Director joins Avalere; more personnel announcements in this month’s column.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS072924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel